Federal health officials held closed door conversations with prominent technology companies last month as the health department and its subagencies aim to safely boost adoption of clinical artificial intelligence.

During a July 8th “clinical AI demo day” at the Food and Drug Administration’s White Oak headquarters, officials from the FDA and the Centers for Medicare and Medicaid Services hosted leaders from 10 companies, according to an agenda for the event reviewed by STAT: Anthropic, Counsel Health, Curai, K Health, Microsoft AI, Amazon One Medical, Doctronic, Ellipsis Health, Hippocratic AI, and Welldoc.

STAT spoke with four companies that attended, Counsel Health, K Health, Hippocratic AI, and Ellipsis Health, who summarized their comments to regulators. The meeting was meant to offer federal health officials first-hand experience with AI doctor technology as it exists today. For the assembled companies, including powerful technology giants and startups funded by influential investors like Andreessen Horowitz and Khosla Ventures, the event offered a significant opportunity to help shape policy as officials wrestle with regulating health AI and how to pay for it.

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in